Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed study CLDT600ACN04 study and will be available to immediately rollover into this study without discontinuation of study drug.~* Patient was not discontinued from the previous CLDT600ACN04 study.~* Adult patients with CHB (HBeAg positive or HBeAg negative).~* HBV DNA PCR undetectable in recent 12 months.~Exclusion Criteria:~* Pregnant or breastfeeding, or has plan of pregnant during study period.~* Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV at screening visit.~* Patient has received within the past 12 months any anti-HBV treatment combination (add-on therapy) or switch to other anti HBV treatment from Telbivudine at investigator's discretion.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).